Head and neck cancers
Invited discussant abstracts 949O and 954O
Date
10 Oct 2016Session
Head and neck cancersPresenters
Sandrine FaivreAuthors
S. FaivreAuthor affiliations
- Cancérologie (oncology), Hôpital Beaujon, 92110 - Clichy/FR
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3883 - Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC)
Presenter: Julie Bauman
Session: Head and neck cancers
Resources:
Abstract
2639 - Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055
Presenter: Robert Haddad
Session: Head and neck cancers
Resources:
Abstract
2031 - A comparative study of PD-L1 diagnostic assays in squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Marianne Ratcliffe
Session: Head and neck cancers
Resources:
Abstract
Invited discussant abstracts LBA36, 957PD and 955PD
Presenter: Ulrich Keilholz
Session: Head and neck cancers
Resources:
Slides
Webcast
866 - PET-CT surveillance for advanced head and neck cancer: a cost-effective alternative to planned neck dissection?
Presenter: Alison Smith
Session: Head and neck cancers
Resources:
Abstract
3149 - Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses
Presenter: Marcia Brose
Session: Head and neck cancers
Resources:
Abstract
2042 - Development of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN)
Presenter: Amy Prawira
Session: Head and neck cancers
Resources:
Abstract
Invited discussant abstracts 952PD, 953PD and 956PD
Presenter: Ricard Mesia Nin
Session: Head and neck cancers
Resources:
Slides
Webcast
2085 - Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort
Presenter: Neil Segal
Session: Head and neck cancers
Resources:
Abstract
Slides
Webcast
1192 - Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies
Presenter: Laurie Gay
Session: Head and neck cancers
Resources:
Abstract
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.